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Recent investigations have made considerable progress in the understanding of tissue
regeneration driven by mesenchymal stromal cells (MSCs). Data indicate the anatomical
location of MSC as residing in the “perivascular” space of blood vessels dispersed
across the whole body. This histological localization suggests that MSCs contribute to
the formation of new blood vessels in vivo. Indeed, MSCs can release angiogenic factors
and protease to facilitate blood vessel formation and in vitro are able to promote/support
angiogenesis. However, the direct differentiation of MCSs into endothelial cells is still
matter of debate. Most of the conflicting data might arise from the presence of multiple
subtypes of cells with heterogeneous morpho functional features within the MSC
cultures. According to this scenario, we hypothesize that the presence of the recently
described Mesodermal Progenitor Cells (MPCs) within the MSCs cultures is responsible
for their variable angiogenic potential. Indeed, MPCs are Nestin-positive CD31-positive
cells exhibiting angiogenic potential that differentiate in MSC upon proper stimuli. The ISCT
criteria do not account for the presence of MPC within MSC culture generating confusion
in the interpretation of MSC angiogenic potential. In conclusion, the discovery of MPC
gives new insight in defining MSC ancestors in human bone marrow, and indicates the
tunica intima as a further, and previously overlooked, possible additional source of MSC.
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DISCOVER, ISOLATION, AND CHARACTERIZATION OF MSCs
In the late sixties, A. J. Friedenstein and coworkers first
described the multipotent mesenchymal stromal cells (MSCs).
When human bone marrow (BM) cells were cultured in plas-
tic dishes colonies of adhered fribroblastoid cells proliferate and
hematopoietic precursors progressively disappear. These cells
have been named Colony Forming Units of Fibroblastoid cells
(CFU-Fs) because of their ability to form large colonies on plas-
tic surfaces. MSCs are able to differentiate into chondrocytes
and osteoblasts, in vitro (Friedenstein et al., 1968), and in vivo
(Friedenstein et al., 1974). By that time, T. M. Dexter and col-
leagues developed a culture system to study hematopoiesis and
demonstrated that bonemarrow hematopoietic stem cells (HSCs)
were unable to adhere onto the culture flasks but necessitate an
underlying layer of adherent cells that mimics the bone marrow
stromal compartment (Dexter et al., 1977). After the demon-
stration that CFU-Fs originate from the bone marrow stroma,
their name was changed in bone marrow stromal cells (Lanotte
et al., 1981). In 1991, A. I. Caplan suggested the presence of a
stem cell population in the adult BM able to differentiate into
multiple mature cell lineages sharing a common precursor in
the mesodermal layer of the embryo. Therefore, these cells were
named “mesenchymal stem cells” (Caplan, 1991). Subsequently,
the differentiation potential of MSCs into multiple mature lin-
eages has been confirmed: these cells have a stable phenotype that
can be easily expanded in culture and maintain the ability to dif-
ferentiate into osteoblasts, chondrocytes, adipocytes, tenocytes,
myocytes and stromal cells supporting hematopoiesis (Pittenger
et al., 1999). MSCs became popular when K. Le Blanc et al.
showed that MSCs are “invisible” to the immune system because
they express only the class I Major Histocompatibility Complex
(MHC-I) but not the class II and co-stimulatory molecules such
as CD40, CD80, and CD86. This is relevant in the prospective of
allogeneic transplantation with possible therapeutic applications
(Le Blanc et al., 2003).
The isolation and the expansion of MSCs are easily feasi-
ble from the adult bone marrow in most cellular laboratories.
Therefore, MSCs have been largely evaluated and employed in
several premature clinical trials. However, a precise characteriza-
tion of these cells is still missing as well as standardized protocols
for their isolation and expansion. Consequently, results are con-
troversial and the biology of MSCs is still unclear.
More recently, the International Society for Cellular Therapy
(ISCT) has proposed minimal criteria to define MSCs (Dominici
et al., 2006):
(1) MSCs are plastic-adherent cells in standard culture
conditions,
(2) MSCs express the surface marker: CD105, CD73, and CD90
and do not to express the hematopoietic markers: CD45,
CD34, CD14, and CD11b, and
(3) MSCs must be able to differentiate toward osteogenic, adi-
pogenic and chondrogenic lineages when exposed to the
proper conditions in vitro.
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Finally, MSCs have been re-named “mesenchymal stromal cells”
modifying the term “stem” into “stromal” in order to maintain
the same acronym and avoid possible over-interpretation of their
limited pluripotent potential (Horwitz et al., 2005).
TISSUE ORIGINS AND DISTRIBUTION OF MSCs
Cells matching the ISCT criteria can be isolated not only from the
bone marrow but also from other adult and the fetal tissues (De
Bari et al., 2001; Zuk et al., 2001; In’t Anker et al., 2004; Seo et al.,
2004). In these studies the culture condition adopted to establish
BM-derived MSCs were applied to cells isolated from other tis-
sues, in order to determine if MSCs reside also in different organs.
In mice, L. da Silva Meirelles et al. demonstrated that long-term
culture of MSCs could be established from a wide range of dif-
ferent adult tissues including fat, muscles, pancreas, vena cava,
kidney glomerulus, aorta, brain and many others alongside bone
marrow (da Silva Meirelles et al., 2006). Notably, all the cell pop-
ulations that L. da Silva Meirelles established, independently from
their origin, were long-term culture of adherent cells, with MSC
phenotype and able to differentiate into mesenchymal cell lin-
eages. These data suggest the presence of MSCs in virtually in all
organs and tissues of the body. Three hypotheses try to explain
the tissue distribution of MSCs:
(1) MSCs permanently reside in multiple tissues and organs,
(2) MSCs reside in only in particular tissues but can circulate in
blood, and
(3) MSCs are circulating blood cells.
The presence of CFU-Fs in blood of adult mammals was shown
in 2007 (He et al., 2007). However, the contamination with frag-
ments of connective tissue could not be ruled out to justify
the presence of MSCs in the collected sample. Disputes remain
regarding the existence of circulating MSCs (Roufosse et al.,
2004; Kuznetsov et al., 2007). L. da Silva Meirelles demonstrated
the presence of MSCs within tissue cleaning the organs using
intravascular perfusion before their collection. Nonetheless, the
possibility that MSCs may circulate locally or systemically under
non-physiological conditions, i.e., tissue injury, is not excluded.
Although, the features of MSC from different organs are similar,
mild differences in differentiation potential and surface mark-
ers have been reported. These differences have been related to
the influence of a modified local environment (niche) present in
different site of the body.
MSC can be isolated from the wall of blood vessels (Doherty
et al., 1998; Bianco et al., 2001), and in 2007, B. Sacchetti et al.
demonstrated a common phenotype for BM-derived CFU-Fs
and Adventitial Reticular cells (ARCs). ARCs populate sinu-
soids and lay in close contact with the endothelium. Strong
evidence indicate that the fibroblastoid colonies described by
Friedenstein in vitro originate from the ARCs isolated ex vivo
(Sacchetti et al., 2007). Stromal progenitors in human BM that
reside in the sub-endothelial layer of sinusoids strongly express
the melanoma-associated adhesion molecule (MCAM/CD146).
A. Tormin et al. confirmed that CD271 is an in vivo marker of
BM-derived MSCs (Quirici et al., 2002) and described a sub-
set of CD271+ cells that express CD146. Cells expressing CD271
and CD146 are the ARCs present in the sub-endothelial layer of
sinusoids. The remaining CD271+/CD146− cells maintain the
MSC features but in vivo reside in the trabecular bone-lining
endosteal niche (Tormin et al., 2011). Therefore, there are at least
two cells able to generate MSCs from the bone marrow one in the
perivascular (CD271+/CD146+) and one in the endosteal niche
(CD271+/CD146−).
M. Corselli et al. isolated two distinct MSC progenitors from
the stroma vascular fraction (SVF) of the adipose tissues (Corselli
et al., 2012). CD34−CD146+ pericytes encircling capillaries and
microvessels and CD34+CD146− adventitial cells surrounding
larger arteries and veins. MSC-like cultures can be expanded from
both these populations, suggesting a vascular origin for the MSCs
of the adipose tissue, similarly to what observed in bone marrow.
A hierarchical organization of cell differentiation has been pro-
posed for the vascular progenitor of MSCs being the adventitial
cells the precursors of pericytes. Indeed, under proper conditions,
ARCs differentiate into pericytes in vitro. Later, M. Crisan et al.,
isolating the cells through CD146, demonstrated the perivascular
origin of MSCs in multiple organs (Crisan et al., 2008).
A new hypothesis that MSCs are localized in vivo in “perivas-
cular” spaces that extend through the whole post-natal organism
has been proposed. While this latest hypothesis is gaining con-
sensus among researchers, the term “perivascular” is somehow
ambiguous because it include the proximity of vessel and the
wall itself. More precisely, two intra-vessel wall compartments,
the adventitia and sub-endothelium, have been indicated as pos-
sible locations for these two MSC progenitors. The relationship
between these two progenitors remains obscure, even if they have
been largely characterized. Their histological localization, sug-
gests a role of MSC in blood vessel formation in vivo. MSCs
can directly differentiate into vascular cells (endothelial cells
and smooth muscle cells) and/or as supporting vascular (re)-
generation in response to the paracrine secretion of stimulating
factors (Lin and Lue, 2013).
CONTROVERSIES ABOUT THE ANGIOGENIC POTENTIAL OF
MSCs
One of the most interesting debates regarding MSCs concerns
their angiogenic potential. Due to the possible role of MSC in
therapeutic (re)-vascularization, an increasing number of stud-
ies in vitro and in vivo have been performed (reviewed in Vittorio
et al., 2013).
The formation of new blood vessel can be divided in:
(1) Vasculogenesis: de novo formation of blood vessels from the
endothelial precursors or angioblasts,
(2) Angiogenesis: includes sprouting of existing vessels and
intussusceptive angiogenesis, and
(3) Arteriogenesis: remodels a pre-existing collateral circulation
(Makanya et al., 2009; van Royen et al., 2009; Melero-Martin
et al., 2010; Carmeliet and Jain, 2011; Potente et al., 2011).
Although MSCs support these processes through the release of
angiogenic factors and protease (reviewed in Watt et al., 2013),
the relevance of their differentiation into endothelial lineages is
still debated.
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The demonstration of MSC commitment toward endothe-
lial lineage is often limited to the detection of the upregulation
of typical EC surface molecules including CD31, CD34, VEGF
receptors (VEGFR1, VEGFR2) and vonWillebrand factor (vWF).
As phenotype modification is insufficient to demonstrate differ-
entiation, additional functional tests are often performed. These
tests include in vitro tube formation on Matrigel® and uptake
of acetylated-low density lipoproteins (Ac-LDL). Nonetheless, it
might be inaccurate describing these differentiated MSCs as fully
mature and functional ECs basing on these in vitro assays. For
example, Ac-LDL uptake has been described also in macrophages
and pericytes (Voyta et al., 1984).
A large effort was spent for the optimization of protocols
able to induce endothelial differentiation of MSCs. VEGF stim-
ulates the differentiation of MSCs into ECs. In 2004, J. Oswald
et al. demonstrated that confluent human BM-derived MSCs
cultured in 2% fetal calf serum (FCS) and 50 ng/ml VEGF for
a week, displayed upregulation of endothelial surface markers
including VEGFR1, VEGFR2, VE-Cadherin, VCAM-1, and vWF.
Moreover, when incubated on Matrigel® in vitro, MSCs formed
characteristic capillary-like structures (CLS) (Oswald et al., 2004).
Similarly, M. Jazayeri et al. cultured human BM-derived MSCs
in medium supplemented with 5% FCS, IGF and VEGF and
detected CD31, vWF, Tie2, VCAM1, and VE-cadherin on the
cell surface. In addiction, applying electron microscopy Authors
showed the presence of typical ECmorphological features includ-
ing Weibel-Palade bodies, tight junctions and caveolae (Jazayeri
et al., 2008). Similar results were also achieved using “endothelial
growth medium-2” (EGM-2, which contains VEGF, EGF, FGF-
2, IGF-1, hydrocortisone, heparin, ascorbic acid and 2% FCS)
(Liu et al., 2007) and MSCs isolated from the adipose tissue (Cao
et al., 2005; Fischer et al., 2009). Conversely, V.D. Roobrouck et al.
reported that VEGF treatment of human BM-derived MSCs sig-
nificantly increased mRNA expression of CD34, VEGFR1, and
VEGFR2, but not of Tie-2 and vWF or CD31 that was even
decreased. These MSCs also failed forming CLS in Matrigel®
assays, (Roobrouck et al., 2011). In parallel, W. Fan et al. demon-
strated that human BM-derived MSCs cultured in the presence of
different concentrations of VEGF did not show increase in CD31,
vWF or VEGFR2 expression (Fan et al., 2011).
In vivo G. V. Silva et al. demonstrated that MSCs applied in
a region of myocardial ischemia can differentiate into smooth
muscle cells and endothelial cells leading to increased vessel den-
sity and an improvement the cardiac function, in a canine model
(Silva et al., 2005). Nonetheless, there is a consolidating concept
that the angiogenic effect of MSCs is predominantly caused by
their paracrine actions rather than their EC trans-differentiation
potential. A. Al-Khaldi et al. showed that, in themurineMatrigel®
plug assay, more than 99% of the new-formed blood vessels orig-
inated from host-derived EC, while a small portion of injected
BM-derivedMSCs were found in the close proximity of- or within
blood vessels (Al-Khaldi et al., 2003). Moreover, the observa-
tion that MSCs in vitro committed through endothelial lineages
were not superior to “naïve” MSCs in stimulating in vivo angio-
genesis, may underline the relevance of the secretion of pro-
angiogenic factors that is also sustained by uncommitted MSCs
(Liu et al., 2007; Fan et al., 2011). Thus, the up-regulation of
endothelial marker, under specific culture conditions, could rep-
resent an in vitro artifact and not a real differentiation into
functional endothelial cells. BM-derived MSCs seems to be an
important regulator of neo-vascularization by the secretion of
pro-angiogenic factors as well as by differentiating into functional
pericytes able to stabilize the new-formed vasculature (Au et al.,
2008), rather than a source of endothelial progenitor cell.
Most of the controversial data about endothelial differen-
tiation of MSCs need to be discussed as consequence of the
sub-optimal protocols of differentiation (Janeczek Portalska et al.,
2012). Moreover, a critical issue is the heterogeneity of the pri-
mary MSC cultures used to generate endothelial progenitors.
HETEROGENEITY OF CULTURE EXPANDED MSCs
The anatomic localization and the physiological function ofMSCs
are not clearly characterized. MSCs are commonly isolated from
long-term cultures; therefore, it remains difficult to determine the
primary cells of origin. The loose ISCT criteria hamper the iden-
tification of unique precursors of MSCs. Indeed, several types of
primary cells with different features can fulfill the definition of
MSCs in vitro. Being the definition permissive, the presence of a
unique common precursor for cells with MSC features cannot be
hypothesized. In BM, MSCs can originate from both perivascular
and endosteal progenitors, therefore, it is difficult to distinguish
if there is a unique common precursor or if the loose ISCT
definition is unable to identifies two different progenitor popula-
tions. However the clinical applications ofMSCs are only partially
limited by the incomplete characterization of the progenitor
cells.
The heterogeneity of MSC cultures, defined according to ISCT
criteria, is becoming evident in more recent articles and brings
into question the utility of these ambiguous criteria. From the
beginning, different terms have described the morphology of
plastic-adherent cells: fibroblastoid (Werts et al., 1980), giant fat
cells and blanket cells (Allen and Dexter, 1983), spindle shaped
flattened cells (Kuznetsov et al., 1997) and very small round cells
(Colter et al., 2001). Thus, mesenchymal cell morphology seems
to be highly dependent on culture conditions: supplements, seed-
ing density, number of passages and culture time (Wagner and
Ho, 2007; Barachini et al., 2009). It is still unclear if there is any
relation between these different morphology and cell functions.
There is not a consensus on the surface markers of MSCs, aside
from the unspecific CD105, CD90, CD44, and CD73, because
different laboratories use different sets of antigens. Therefore,
the differentiation into mature cells with a mesengenic ances-
tor seems to be the more reliable and stringent criteria to define
MSCs. However, the differentiation potential of MSC is variable.
This variability is observed between different donors (Phinney
et al., 1999) and also within different colonies obtained from
the same subject (Russell et al., 2010). Indeed, colonies obtained
from the same individual could be characterized as mono-, bi-
or tri-potent on the basis of their ability to differentiate into,
respectively one, two or three types of tissue: osteogenic, chon-
drogenic and adipogenic lineages. Moreover, it has been clearly
demonstrated that repeated passages progressively reduce the
multi-lineage differentiation ability, introducing a further ele-
ment of complexity (Muraglia et al., 2000). It is possible to
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hypothesize that the angiogenic potential of MSC is subject to a
similar variability that is influenced by the same factors.
MSCs are heterogeneous not only among different colonies
but also within the same colony (Digirolamo et al., 1999). Cells
show variable differentiation potential in relation to their topo-
graphic localization inside the colony. Cells from the center and
the margins of the colony differ for shape, differentiation poten-
tial and surface markers (Ylöstalo et al., 2008; Sengers et al.,
2010). Therefore, the term “multipotent mesenchymal stromal
cells” does not identify a population of cells with uniform features
and unambiguous potential but refers to a highly heterogeneous
population that is dramatically affected by donors characteristics
(Russell et al., 2013), isolation methods (Wagner and Ho, 2007;
Barachini et al., 2009), culture conditions (Bieback et al., 2009).
Several possible mechanisms may explain the basis of the MSC
heterogeneity, beside the already described variability introduced
by ex vivo procedures (Pevsner-Fischer et al., 2011). Hypotheses
on the origin of this variability include: stochastic events, occur-
ring during expansion and differentiation and a possible in vivo
heterogeneity of the isolated cell populations. In this latter
hypothesis, specific culture conditions select, or simply promote,
particular subpopulations of MSCs giving reason of the observed
heterogeneity and the morpho-functional variability. According
to this scenario, numerous multipotent cell populations can be
described in bone marrow, some of them able to differentiate into
lineage from the three germ layers: endoderm, mesoderm and
ectoderm (triploblastic differentiation). However, the isolation
and successive characterization of these cells is strictly dependent
on the application of specific culture conditions. For example,
“marrow-isolated adult multipotent inducible (MIAMI)” cells
can differentiate into, neural and pancreatic-like cells in addition
to skeletal tissue lineage (D’Ippolito et al., 2004). The isolation
and expansion of MIAMI cells require specific culture conditions
with low oxygen tension.
Recently a unique multipotent sub-population in adult human
BM-derived MSCs has been isolated using fluorescent activated
cell sorting (FACS) for stage-specific embryonic antigen 3 (SSEA-
3). BM-derived MSCs show poluripotency-differentiation prop-
erties (Kuroda et al., 2013). Interestingly, stress conditions could
enrich the expression of SSEA-3 in cultured MSCs (Kuroda et al.,
2010). Y. Kuroda et al. demonstrated that long-term trypsin
incubation could increase the recovery of cell clusters contain-
ing pluripotency-associated markers and renamed these cells as
“multi-lineage differentiating stress-enduring” (MUSE) cells.
Thus, if mild modifications in the culture conditions, or in the
culture procedures, can induce/preserve an embryonic-like differ-
entiation potential in BM-derived cells, it is reasonable to suppose
that angiogenic potential behaves similarly and is significantly
affected by manipulation in vitro.
MESODERMAL PROGENITOR CELLS (MPCs) IN ADULT
HUMAN BONE MARROW
In 2007, we attempted to optimize MSC culture conditions for
clinical application selecting media without supplements of ani-
mal origin. When medium was supplemented with autologous
serum instead of that of bovine origin, a small population of cells
with distinct shape was noticed. These cells presented rounded,
fried-egg shape, instead of the usual spindle morphology of
MSCs, were highly refractive and remain firmly attached to the
plastic during trypsin digestion
In 2008, by replacing fetal bovine serum (FBS) with pooled
human AB serum (PhABS) in the culture medium of human
BM cells, we were able to characterize this new population of
adherent cells (Petrini et al., 2009). These cells are quiescent:
Ki-67 negative; with long telomeres and express the pluripotency-
associated transcription factors Oct-4 and Nanog instead of
RUNX2 and Sox9 typical for MSC-phenotype (Pacini et al.,
2010). Phenotypically, these cells share the expression of CD105
withMSCs but lacked expression of CD73, CD90, CD166, CD271
and those other markers typical of the mesenchymal phenotype
such as MSCA-1. Interestingly, this cell population rapidly pro-
duces mesenchymal offspring when supplemented with FBS or
human cord blood serum. Thus, this novel population of cells,
isolated from the BM, has in vitro characteristics of a progen-
itor of the mesengenic lineage and therefore has been named
“Mesodermal Progenitor Cells” (MPCs).
ISOLATION OF MPCs FROM HUMAN BM SAMPLES
Method for the isolation of MPCs from BM samples is feasible,
inexpensive and based on selective culture conditions (Trombi
et al., 2009). Initially, MPCs were co-isolated together with MSCs
applying media supplemented with autologous serum or PhABS,
in culture. It became evident that MPCs have different adhe-
sion properties compared to MSCs. In fact, applying standard
trypsin-based cell detaching protocols, MSCs were entirely har-
vested while most of the MPCs remain firmly attached to the
plastic surface and required different proteases’ solution (TrypLE
Select® from LifeTechnologies) to be detached. Therefore, plastic
features and coating of the culture surfaces influence the propor-
tion of MPCs and MSCs in the primary cultures. We firstly tested
not gas-treated hydrophobic plastics, usually applied for cultures
in suspension, and surprisingly MPCs were able to attached on
that surface also. Conversely, the hydrophobic conditions resulted
not permissive for MSC. Thus, a selective culture could be estab-
lished using these conditions allowing the recovery of MPCs with
a purity of more than 95%. We also noticed that a higher yield of
MPC recovery was achieved using higher seeding densities, than
that usually applied for MSC isolation. In summary, PhABS sup-
plementation and high density seeding on hydrophobic plastics
were the selective culture conditions necessary for MPCs isola-
tion from BM-MNCs. This method has been consolidated and it
is highly reproducible allowing the quality screening of the MPC
preparations before their employment in the different studies.
The mechanisms behind the difference, in MPC recovery,
between culturing cells in FBS or PhABS-containing medium are
still unknown. Nonetheless, we demonstrated that the addition of
PhABS, even in small percentages, to FBS primary cultures allows
MPC isolation, suggesting the presence of undetected agents able
to induce MPCs in the human serum (Trombi et al., 2009).
Conversely, when FBS is added to cultures grown in PhABS, cells
differentiate into MSCs without any significant reduction in the
number of MPCs indicating a possible semi-conservative prolif-
eration of MPCs. What characterized FBS against PhABS is the
different origin in terms of species (bovine instead of human) and
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stage of body development (fetal against adult). The differentia-
tion of MPCs into MSCs is induced replacing PhABS with FBS
(Petrini et al., 2009), or using human cord blood-derived serum
(unpublished data). These preliminary results suggest that media
supplementation with fetal sera represent the culture condition
for the mesengenic induction of MPCs, independently from the
adopted species.
Mesengenic potential of MPCs
Later, we have been able to demonstrate a hierarchical multi-
step model of mesenchymal differentiation with at least three
different populations of multi-potent cells (Fazzi et al., 2011).
Indeed, MPCs can generate exponentially growing MSC cultures
after 2 weeks of stimulation with differentiating conditions. The
differentiation proceeds through the commitment into an inter-
mediate cell population; we named early MSCs. Timing of MPC
mesengenic differentiation was definitively clarified and specific
morphologies, phenotypes and growing features of the three pro-
tagonists described (Figure 1A). Studying Wnt signaling activa-
tion during MPC differentiation, we showed that non-canonical
Wnt5/Calmodulin pathway was involved in the commitment of
MPCs into early MSCs and demonstrated that Calmidazolium
Chloride, a Calmodulin inhibitor, was able to interfere with the
differentiation only at this initial step while has no effect on
passage from early to lateMSCs.
Angiogenic potential of bone marrow-derived MPCs
From the beginning it has been clear that MPCs have angio-
genic potential because they form capillary-like structures (CLS)
after a multiple steps of differentiation (Petrini et al., 2009;
Trombi et al., 2009; Pacini et al., 2010). Interestingly, the
inhibition of the Wnt5/Calmodulin signaling pathway has no
effects on the MPC differentiation toward endothelial lineage
suggesting that Wnt signaling pathway activation finely regu-
lates MPC fate. On the contrary of mesengenic, all the pas-
sage of angiogienic differentiation have not been described to
date due to the lack of specific culture protocols. Indeed, to
partially induce endothelial differentiation we applied proto-
cols optimized for endothelial progenitor cells (EPCs) with mild
modifications (Hill et al., 2003). This was sufficient to demon-
strate the angiogenic potential of MPCs and suggested that
exist a BM-derived endothelial progenitor cell distinct from
EPCs.
The high expression of CD31 and Nestin in MPCs suggest the
existence of a primitive progenitor for the endothelial lineages
(Petrini et al., 2009; Trombi et al., 2009; Pacini et al., 2010). Nestin
is a class VI intermediate filament protein originally described as
a marker of neural stem cells that is expressed during the devel-
opment of central nervous system (CNS) (Lendahl et al., 1990).
Although Nestin expression is down regulated during the dif-
ferentiation into neurons or glial cells (Dahlstrand et al., 1995),
it can be detected in adult neural progenitor cells (Reynolds
et al., 1992; Morshead et al., 1994) and in some CNS tumors
(Tohyama et al., 1992). Frequently, Nestin is not expressed by the
cancer cells themselves but can be observed in the endothelial
cells of the tumor regardless of malignancy grade or its histo-
type (Sugawara et al., 2002). This suggests that Nestin can be a
marker of proliferating tumor endothelial cells and not only of
neuroepithelial elements. Therefore, Nestin expression correlates
with angiogenesis because it is expressed in proliferating vascu-
lar endothelial cells of the tumor (Kim et al., 2002; Teranishi
et al., 2007; Gravdal et al., 2009; Eaton et al., 2010). K. Sugawara
et al. demonstrated a high expression of Nestin in bovine aor-
tic proliferating endothelial cells in static culture. This expression
rapidly decreases under conditions of laminar shear stress flow,
suggesting that Nestin expression is typical of early proliferat-
ing endothelial precursors but is loss in mature endothelial cells
of normal tissues. In the recent years, the emerging concept
of Nestin as a novel early angiogenic marker is gaining con-
sensus in normal ad tumor angiogenesis (reviewed in Matsuda,
2013).
MPCs express CD31/PECAM (Pacini et al., 2013) but rapidly
loose these markers during differentiation contextually with the
lost of Nestin (Figure 1A). Preliminary data show that MPCs can
make “sprouting” when directly seeded in Matrigel® 3D-cultures
but are not able to efficiently form CLS without a step of pre-
differentiation. Therefore, MPCs could represent a very staminal
progenitor with angiogenic potential more immature than what
is reputed to date.
MPCs DO NOT SHOW FEATURES OF PERICYTES OR
ADVENTITIAL PROGENITORS
Pericytes surround blood capillaries, precapillary arterioles, post-
capillary venules and collecting venules (Sims, 1986; Allt and
Lawrenson, 2001); where they can be identify by the expression of
CD146 together with less specific markers such as α-smoothmus-
cle actin (α-SMA), desmin, NG-2, platelet-derived growth factor
receptor (PDGFR)-α, aminopeptidase A and N, RGS5, and the
promotertrap transgene XlacZ4 (Gerhardt and Betsholtz, 2003).
Pericytes and Adventitial Progenitor Cells (APCs) belong to
the same cell lineage, according to several authors (Tormin et al.,
2011; Corselli et al., 2012). Pericytes and APCs differ in their
position in the vessel wall morphology, and some surface mark-
ers. However, this distinction is not absolute because exist a
continuum between the phenotype of the classical APCs and
the typical pericytes when they are distributed along small ves-
sels such as arteriole, capillary, and venule. It has been sug-
gested that pericytes may reside under the endothelium even
in large vessels and support the endothelial removal and repair
after injuries. From this point of view, these cells can be con-
sidered a reservoir of MSC-like undifferentiated cells (da Silva
Meirelles et al., 2006). Conversely, Corselli’s data demonstrated
that APCs differentiate into pericytes in vitro, suggesting a
“centripetal” (from the adventitia toward sub-endothelial layer)
relationship between these cells (Corselli et al., 2012). Both
the “centrifugal” and the “centripetal” model assumed that the
intima would not be involved in the generation of MSC-like
cells.
Interestingly, our MPCs express the early angiogenic mark-
ers Nestin and CD31/PECAM, suggesting their plausible loca-
tion in the tunica intima. Although the localization of MPCs
in the lumen-facing wall of vessels has been not definitively
demonstrated, preliminary histological evaluations revealed the
expression of Nestin in the sinusoids, arterioles/venules and larger
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FIGURE 1 | The angiogenic potential of MSC cultures is controversial.
(A) Mesodermal Progenitor Cells (MPCs) are CD90-, Nestin+ progenitors of
MSCs. These cells remain in a quiescent state presenting a typical fried
egg-shape, condensed chromatin and podosomal structures. When
mesengenic differentiation is induced, MPCs differentiate into “early MSCs.”
Early MSCs slowly proliferate, express Nestin and CD90 (a MSC marker) and
modify their shape because of Actin re-organization in focal adhesion
complexes. Under persistent stimulation toward mesengenic differentiation,
“early MSC” become “late MSC” showing exponentially growth,
fibroblastoid shape and the ability to differentiate into skeletal tissues (fat,
bone and cartilage). (B) According to this hierarchical model, MPCs can be
considered a putative progenitor of the mesenchymal lineage in vivo, being
present in the bone marrow mononuclear fraction. When supplemented with
media containing FBS, these cells rapidly differentiate toward the
mesengenic lineage and form asynchronous and heterogeneous cultures
fulfilling the ISCT MSC criteria of definition. The undetected and
unpredictable presence of sub-populations of MPCs, in culture could explain
the variable angiogenic potential described for MSC in the literature.
Conversely, the isolation of MPC and their subsequent differentiation using
optimized protocol can allow the generation of synchronized and
homogeneous mesenchymal stromal cells with a reproducible angiogenic
potential.
vessels of bone marrow (Figure 2). A higher Nestin expression
was observed in sinusoids’ endothelium, whereas a lower Nestin
expression was localized in only few cells located in the sub-
endothelium and adventitia.
MPC do not express CD146, a specific markers of per-
icytes, as well as CD271. Therefore, it is unlikely MPCs
reside in the adventitia or in the sub-endothelium (Petrini
et al., 2009; Trombi et al., 2009; Pacini et al., 2010).
Thus, any model of perivascular localization of MSC-
like cells will be incomplete without the inclusion of
the tunica intima among the possible sources of these
cells.
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FIGURE 2 | Nestin expression in human bone marrow biopsies. (A)
Consistent expression of Nestin is detectable in the tunica intima of
large vessels, arterioles and venules (dark brown color). Few cells of
the sub-endothelium and adventitia show a weakly positive Nestin
staining (light brownish color). Furthermore, Nestin is highly expressed
in the sinusoids and two colors immunofluorescence reveals that
Nestin is positive in lumen-facing cells surrounded by CD146+/Nestin−
pericytes. (B) Schematic representation of possible tissue distribution
of MPC (represented in green) and other bone marrow
vessels-residing cells.
NEW HYPOTHESIS ON ANGIOGENIC PROPERTIES OF
BM-DERIVED MULTIPOTENT STROMAL CELLS
Recently, we have proposed that the yield of MPCs, co-isolated
in the standard BM-MSC preparations, is influenced from the
host, the batches of the serum and from the density of cell seeding
(Petrini et al., 2009). The inter-population variability introduced
by different donors and cell isolation protocols, affect the yield
of MPCs, early MSCs or late MSCs. According to the hierarchi-
cal model, MPCs are progenitors of the mesenchymal lineage
and account for 1–3% of mononuclear cells of the bone marrow
(BM-MNCs). When BM-MNCs are seeded in standard FBS-
containing media MPCs rapidly differentiate into mesengenic
lineages forming the typical MSC culture in few days.
The variable angiogenic potential described in the literature
of MSCs is probably related to the heterogeneous composition
of the cultures expanded from the bone marrow that includes
sub-populations of MPCs and MSCs when defined according
to ISCT criteria (Figure 1B). Indeed, the expanded or exponen-
tially growing MSCs are Nestin-negative and de facto coincide
with our late MSCs. Late MSCs do not retain any angiogenic
potential because these cells are already committed toward other
mesengenic lineage (Figure 1B). Most of the reports do not apply
specific protocols for MPC’s isolation; thus, these MSC cultures
represent an uncontrolled heterogeneity of multipotent cells with
an unpredictable angiogenic potential. Because MPCs show resis-
tance to trypsin digestion, these cells are expected to be lost
during subsequent passages reducing progressively the angiogenic
potential of the sub-cultures. Not surprisingly, the most suc-
cessful endothelial differentiation protocols have been obtained
from early passages of MSC’s cultures (Oswald et al., 2004; Fan
et al., 2011; Janeczek Portalska et al., 2012). Conversely, protocols
specific for endothelial differentiation may commit a pure popu-
lation of MPCs into homogeneous clones of MSCs. The clinical
utility of BM-derived cells will be improved by a more precise
phenotypization able to distinguish MPCs from early and late
MSCs.
Recently, Frenette’s group demonstrated in the hematopoi-
etic niche the presence of Nestin-positive bone marrow cells
with mesengenic potential of differentiation. Using Nes-Gfp
transgenic mice, authors identified a highly selected fraction of
www.frontiersin.org May 2014 | Volume 2 | Article 20 | 7
Pacini and Petrini Angiogenic potential of MSC cultures
Table 1 | Bona fide multipotent progenitor cells of bone marrow and adipose tissues.
Acronym MSCs MPCs Pericytes ARCs APCs TBLCs
Phenotype
CD90 + − + + + +
CD105 + + + + + +
CD73 + −
Nestin ± + ±
CD31 − + − − − −
CD146 ± − + − − ±
CD271 + − ± +
CD34 − − − + + −
Distribution Bone marrow
(Pittenger et al.,
1999), adipose tissue
(Zuk et al., 2001) and
many others tissue
cultures (da Silva
Meirelles et al.,
2006)
Bone marrow
cultures (Petrini
et al., 2009)
Sub-endothelium of
vessels and
microvessels in bone
marrow (Tormin
et al., 2011) and
adipose tissue
(Corselli et al., 2012)
Adventitia of vessels
and microvessels in
bone marrow
(Sacchetti et al.,
2007)
Adventitia of vessel
and microvessel in
adipose tissue
(Tormin et al., 2011;
Corselli et al., 2012)
Adjacent to
trabecular bone
(Tormin et al.,
2011)
Role in
angiogenesis
Controversial Sprouting and direct
differentiation into
ECs
Stabilization of new
formed vasculature
Mural cells and
endothelium support
Mural cells and
endothelium support
Not involved
MSCs able to form the HSC niche (Méndez-Ferrer et al., 2010).
In vivo, both in human and mouse, these cells are positive for
PDGFRα, CD51 and Nestin expression and negative for CD45
CD31 CD235a (Ter119- in mice). Although the two types of
BM stem cell can form a single niche, only a small fraction of
Nestin+ cells exhibits MSC activity when tested in mesensphere
or CFU-F assays (Méndez-Ferrer et al., 2010). Also for Nestin-
positive cells, the protocols of isolation and expansion dramati-
cally affect the composition of cell populations in culture; thus
harsh isolation protocols will be needed to avoid the development
of heterogeneous populations and allow the characterization
and functional definition of these interesting cells. Further the
co-expression of PDGFRα and CD51 identifies a subset (about
60%) of Nestin-positive cells with an enriched potential to form
HSC niches and to perform mesenchymal differentiation (Pinho
et al., 2013). Limited data are available regarding the angiogenic
potential of Nestin-positive cells. Because PDGFRα+ CD51+
hematopoietic-supporting stromal cells do not express CD45
(a hematopoietic marker) and CD31 (an endothelial marker), it
can be hypothesized the presence of an additional population of
Nestin-positive CD31-positive cells not described in the previous
analysis.
CONCLUSIONS
Although MSCs have been largely studied for their interest-
ing applications in clinical trials, these cells have not been
fully characterized because of the lack of standardized proto-
cols between different laboratories. Controversies remain, and
several aspects of MSC biology are still unclear. The hetero-
geneity and morpho-functional variability of MSC cell prepa-
rations could explain most of the conflicting data in the
literature. Together with the effects of culture conditions that
can indeed select, or simply promote, particular subpopula-
tions of MSC-like cells (Table 1), the described possible mul-
tiple origins of MSCs contribute to the confusing interpreta-
tion of the experimental data. More stringent phenotypization
criteria may help to prevent this issue. Recently, perivascular
localization of MSC precursors may explain their presence in a
wide range of tissues and organs and suggests some angiogenic
potential.
Therefore, we hypothesize that the presence of the recently
described Mesodermal Progenitor Cells (MPCs) could be respon-
sible for the controversial data regarding angiogenic potential of
MSC cultures. Although these cells can be co-isolated with MSC
culture, different protocols may determine a different yield of
MPCs.
The discovery of Nestin-positive CD31-positive MPCs sup-
ports their role as MSC ancestors in human bone marrow and
indicates the tunica intima as a possible source of MSCs.
Further studies are needed to deeply investigate the MPC biol-
ogy and confirm their anatomical home in human bone marrow.
Nonetheless, the identification of MPCs suggests the opportu-
nity of a revision of the MSC definition in order to achieve their
expected clinical utility (Keating, 2012).
Finally, MPCs represent a valuable cell population for
the proof of new concepts in tissue engineering, where
the neo-vascularization plays a crucial role in the estab-
lishment of successful therapies. Future studies evaluating
MPC-based therapies will take advantage of their mesen-
genic and angiogenic potential in order to regenerate skele-
tal tissues and support their growth with a newly formed
vasculature.
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